Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Drug Cards Daily

#35: potassium citrate (Urocit-K) | An Alkalinizing Agent for Managing Kidney Stones

14 Jun 2021

Description

There are two commonly used forms of potassium. Potassium chloride (to treat hypokalemia) and potassium citrate (as an alkalinizing agent). Unlike potassium chloride, potassium citrate is also measured in “mg” in addition to “mEq”. It comes in a 5 mEq (540 mg), 10 mEq (1080 mg), and 15 mEq (1620 mg) strength ER tablet. The main indication for potassium citrate in in the management of kidney stones. In mild-moderate treatment you initiate 15 mEq PO bid or 10 mEq PO tid with a max dose of 100 mEq per day. Since potassium citrate is an alkalinizing agent the way it works is it makes urine less acidic. It raises the pH of urine to 6-7 which will help rid uric acid from the body. The reduction of uric acid helps manage gout and kidney stones. Since potassium citrate is a known GI irritant it is recommended to take the tablets whole with a glass of water to remain upright after taking it with food or at least within 30 minutes of a meal or snack.  Go to DrugCardsDaily.com for my episode show notes which will contain a drug summary, quiz, and a link to FREE drug card sheets. SUBSCRIBE on Spotify or Apple Podcasts or search for us on your favorite place to listen to podcasts. I will go over the Top 100-200 Drugs as well as throwing in some recently released drugs that peak my interest. Also, if you’d like to say hello, suggest a drug, or leave any constructive feedback on the show I’d really appreciate it! Leave a voice message at anchor.fm/drugcardsdaily or message us through twitter @drugcardsdaily

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.